Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
3944- Shank,    Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies
- Review, AD, NA
*memory↑, *neuroP↑, *Inflam↓, *5HT↑,
3943- Shank,    Protective Mechanisms of Nootropic Herb Shankhpushpi (Convolvulus pluricaulis) against Dementia: Network Pharmacology and Computational Approach
- Review, AD, NA
*neuroP↑, *memory↑, *other↝, *AChE↓, *MAOA↓, *MAOB↓, *TrkB↓, *tau↓, *APP↓, *ROS↓, *Mood↑,
4203- SIL,    Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders
- Review, NA, NA
*MAPK↝, *AMPK↝, *NF-kB↓, *mTOR↝, *PI3K↝, *Akt↝, *BioAv↝, *memory↑, *BDNF↑, *TNF-α↓,
4204- SIL,    Silymarin administration after cerebral ischemia improves survival of obese mice by increasing cortical BDNF and IGF1 levels
- NA, Stroke, NA
*OS↑, *BDNF↑, *IGF-1↑,
3326- SIL,    Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway
- in-vitro, Liver, HepG2 - in-vitro, Liver, Hep3B
*hepatoP↑, chemoPv↑, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓, angioG↓,
3313- SIL,    Silymarin attenuates post-weaning bisphenol A-induced renal injury by suppressing ferroptosis and amyloidosis through Kim-1/Nrf2/HO-1 signaling modulation in male Wistar rats
- in-vivo, NA, NA
*NRF2↑, *HO-1↑, *creat↓, *BUN↓, *RenoP↑, *MDA↓, *TNF-α↓, *IL1β↓, *Cyt‑c↓, *Casp3↓, *GSTs↓, *GSH↑, *GPx4↑, *SOD↑, *GSR↓, *Ferroptosis↓,
3333- SIL,    Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice
- in-vivo, NA, NA
*GRP78/BiP↓, *XBP-1↓,
3332- SIL,    Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2
- in-vitro, Lung, A549
*antiOx↑, *hepatoP↑, MMP2↓, uPA↓, TIMP2↑,
3331- SIL,    The clinical anti-inflammatory effects and underlying mechanisms of silymarin
- Review, NA, NA
*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,
3330- SIL,    Mechanistic Insights into the Pharmacological Significance of Silymarin
- Review, Var, NA
*neuroP↑, *hepatoP↑, *cardioP↑, *antiOx↓, *NLRP3↓, *NAD↑, ROS↓, NLRP3↓, TumCMig↓, *COX2↓, *iNOS↓, *MPO↓, *AChE↓, *LDH↓, *Telomerase↓, *Fas↓,
3329- SIL,    Silymarin regulates the HIF-1 and iNOS expression in the brain and Gills of the hypoxic-reoxygenated rainbow trout (Oncorhynchus mykis)
- in-vivo, Nor, NA
*NO↓, *MDA↓, *TAC↑, *Hif1a↓, *iNOS↓,
3328- SIL,    Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB
- in-vivo, BPH, NA
*NF-kB↓, *Hif1a↓, *PTEN↑, *Weight↓, *NO↓, *IL6↓, *IL8↓, *COX2↓, *iNOS↓,
3327- SIL,    Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia
- in-vitro, Liver, HepG2
MDR1↓, Hif1a↓, P-gp↓,
3325- SIL,    Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury
- in-vivo, Nor, NA
*Inflam↓, *ROS↓, *Casp3↑, *Casp9↑, *Hif1a↓, *iNOS↓, *SOD↑, *MDA↓,
3324- SIL,    Silymarin prevents NLRP3 inflammasome activation and protects against intracerebral hemorrhage
*ROS↓, *TAC↑, *NF-kB↓, *IL2↓, *NRF2↑, *HO-1↑, *neuroP↑, *Inflam↓, *NLRP3↓,
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
3322- SIL,    Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460
HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, HATs↑, Zeb1↓, E-cadherin↑, TumCMig↓,
3321- SIL,    Silymarin (Milk thistle)
- Review, AD, NA
*neuroP↝, *Dose↝, *Half-Life?, *BioAv↝, *cognitive↑, *Aβ↓, *Inflam↓, *OS↑, *memory↑,
3320- SIL,    Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action
- Review, AD, NA
*hepatoP↑, *neuroP↑, *ROS↓, *β-Amyloid↓, *Inflam↓, *Aβ↓, *NF-kB↓, *TNF-α↓, *TNF-β↓, *iNOS↓, *NO↓, *COX2↓,
3319- SIL,    Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *BBB?, *tau↓, *NF-kB↓, *IL1β↓, *TNF-α↓, *IL4↓, *MAPK↓, *memory↑, *cognitive↑, *Aβ↓, *ROS↓, *lipid-P↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *AChE↓, *BChE↓, *p‑ERK↓, *p‑JNK↓, *p‑p38↓, *GutMicro↑, *COX2↓, *iNOS↓, *TLR4↓, *neuroP↑, *Strength↑, *AMPK↑, *MMP↑, *necrosis↓, *NRF2↑, *HO-1↑,
3318- SIL,    Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight
- Review, AD, NA - Review, Park, NA
*hepatoP↑, *neuroP↑, *TLR4↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *memory↑, *cognitive↑, *NRF2↑, *HO-1↑, *ROS↓, *Akt↑, *mTOR↑, *SOD↑, *Catalase↑, *GSH↑, *IL10↑, *IL6↑, *NO↓, *MDA↓, *AChE↓, *MAPK↓, *BDNF↑,
3317- SIL,    Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer's Disease and Other Neurological Disorders
- Review, NA, NA
*neuroP↑,
3316- SIL,  Chemo,    Silymarin Nanoparticles Counteract Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights into Mitochondrial Dysfunction and Nrf2/HO-1 Axis
Inflam↓, antiOx↓, neuroP↑, cognitive↑, NRF2↑, HO-1↑, memory↑, AChE↓, Casp3↓,
3315- SIL,    Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats
- in-vivo, Nor, NA
neuroP↑, *NRF2↑, *HO-1↑, *lipid-P↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *NF-kB↓, *TNF-α↓, *JNK↓, *Bcl-2↑, *BAX↑,
3314- SIL,    Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review
- Review, NA, NA
*antiOx↑, *hepatoP↑, *Half-Life↑, *ROS↓, *GSH↑, *hepatoP↑, *lipid-P↓, *TNF-α↓, *IFN-γ↓, *IL2↓, *IL4↓, *NF-kB↓, *iNOS↓, *OATPs↓, *OCT4↓, *Inflam↓, *PGE2↓, MMPs↓, VEGF↓, angioG↓, STAT3↓, *ALAT↓, *AST↓, Dose↝,
3647- SIL,    Silymarin Modulates Microbiota in the Gut to Improve the Health of Sow from Late Gestation to Lactation
- in-vivo, NA, NA
*IL1β↓, *GutMicro↝, *Inflam↓,
3655- SIL,    Protective effect of silymarin on oxidative stress in rat brain
- in-vivo, AD, NA
*GSH↑, *VitC↑, *SOD↑, *lipid-P↓, *ROS↓, *hepatoP↑, *neuroP↑,
3654- SIL,    Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain
- in-vivo, AD, NA
*ROS↓, *neuroP↑, *GSH↑, *SOD↑,
3653- SIL,    Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress
- in-vivo, AD, NA
*hepatoP↑, *neuroP↑, *cognitive↑, *memory↑, *Inflam↓, *GSH↑, *MDA↓, *Inflam↓, *antiOx↓,
3652- SIL,    Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus
- in-vivo, NA, NA
*hepatoP↑, *other↑,
3651- SIL,    Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease
- Trial, NA, NA
*hepatoP↑, *ALAT↓,
3650- SIL,    Silibinin: a novel inhibitor of Aβ aggregation
- in-vitro, AD, SH-SY5Y
*Aβ↓, *H2O2↓,
3649- SIL,    Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis
*Inflam↓, *NF-kB↓, *cJun↓, *Casp↓, *ROS↓, *lipid-P↓,
3648- SIL,    Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
- Review, NA, NA
*antiOx↑, *Inflam↓, *lipid-P↓, *necrosis↓, *hepatoP↑, *IL1↓, *IL6↓, *TNF-α↓, *IFN-γ↓, MAPK↓, Apoptosis↑, Cyt‑c↑, Casp3↑, Casp9↑, *PPARγ↑, *GLUT4↑, *HSPs↓, *HSP27↑, *Trx↑, *SIRT1↑, *ALAT↓, *GSH↑, *lipid-P↓, *TNF-α↓, TumCG↓, P21↑, CDK4↑,
3646- SIL,    "Silymarin", a promising pharmacological agent for treatment of diseases
- Review, NA, NA
*P-gp↓, *Inflam↓, *hepatoP↑, *antiOx↑, *GSH↑, *BioAv↑, *SOD↑, *IFN-γ↓, *IL4↓, *IL10↓, *Half-Life↓, *TNF-α↓, *ALAT↓, *AST↓, Akt↓, chemoP↑, β-catenin/ZEB1↓, TumCP↓, MMP↓, Cyt‑c↑, *RenoP↑, *BBB↑,
3300- SIL,    Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy
- Review, Var, NA
*ROS↓, *SOD↑, *hepatoP↑, *AST↓, *ALAT↓, *lipid-P↓, *GSH↑, *Catalase↑, *GSTs↑, *GSR↑, *TNF-α↓, *IFN-γ↓, *IL4↓, *IL2↓, *NF-kB↓, *IL10↑, *Inflam↓, COX2↓, Apoptosis↑, ChemoSen↑, PGE2↓, VEGF↓,
3312- SIL,    Silymarin Alleviates Oxidative Stress and Inflammation Induced by UV and Air Pollution in Human Epidermis and Activates β-Endorphin Release through Cannabinoid Receptor Type 2
- Human, Nor, NA
*antiOx↑, *Inflam↓, *ROS↓, *IL1α↓, *AhR↑, *NRF2↑, *IL8↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3302- SIL,    Protective effects of silymarin in glioblastoma cancer cells through redox system regulation
- in-vitro, GBM, U87MG
NRF2↑, HO-1↑, Trx↑, antiOx↑,
3303- SIL,    Exploring the anti-cancer and antimetastatic effect of Silymarin against lung cancer
- Review, Var, NA
chemoP↑, radioP↑,
3304- SIL,    Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells
- in-vitro, GC, AGS - in-vivo, NA, NA
BAX↑, p‑JNK↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, Apoptosis↑, tumCV↓,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,
3306- SIL,  Rad,    Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation
- Review, Var, NA
radioP↑, RadioS↑, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, DNAdam↓, ROS↑, *ROS↓, *Inflam↓,
3307- SIL,    Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications
- Review, Var, NA
*NRF2↑, *antiOx↑, *chemoP↑, *Inflam↓, *BioAv↑, eff↑, *NQO1↑, TNF-α↓, IL6↓, *GSH↑, *ROS↓, *MDA↓, eff↑, *hepatoP↑, *GPx↑, *SOD↑, *Catalase↑, *HO-1↑, *neuroP↑,
3308- SIL,    Structural basis of Nrf2 activation by flavonolignans from silymarin
- Analysis, NA, NA
*antiOx↑, *chemoP↑, *NRF2↑,
3309- SIL,    Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
- Review, NA, NA
*ROS↓, *IronCh↑, *MMP↑, *NRF2↑, *Inflam↓, *hepatoP↑, *HSPs↑, *Trx↑, *SIRT2↑, *GSH↑, *ROS↑, *NADPH↓, *iNOS↓, *NF-kB↓, *BioAv↓, *Dose↝, *BioAv↑,
3310- SIL,    Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro
- in-vitro, Lung, A549
Inflam↓, MPO↓, NO↓, iNOS↓, ROS↓, MDA↑, SOD↑, Catalase↑, GPx↑, NRF2↑, HO-1↑, NADPH↑,
3311- SIL,    Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells
- in-vitro, Nor, PC12
*antiOx↑, *Inflam↓, AntiCan↑, *ROS↓, *MDA↓, *GSH↓, *NRF2↑, *GPx↑, *GCLC↑, *GCLM↑,
3299- SIL,    Silymarin Effect on Mitophagy Pathway in the Human Colon Cancer HT-29 Cells
- in-vitro, Colon, HT29
tumCV↓, MMP↓, ROS↑, selectivity↑,
3298- SIL,    Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells
- in-vitro, BC, MCF-7
LC3II↑, Beclin-1↑, Bcl-2↓, ROS↑, MMP↓, ATP↓, eff↓, BNIP3?, TumAuto↑, eff↑,

Showing Research Papers: 5301 to 5350 of 6108
Prev Page 107 of 123 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6108

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 3,   MDA↑, 1,   MPO↓, 1,   NRF2↑, 3,   ROS↓, 2,   ROS↑, 4,   SOD↑, 1,   Trx↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 3,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   NADPH↑, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↓, 1,   Apoptosis↑, 4,   BAX↑, 2,   Bcl-2↓, 4,   Bcl-xL↓, 1,   Casp3↓, 1,   Casp3↑, 2,   Casp9↑, 3,   Cyt‑c↑, 2,   iNOS↓, 1,   p‑JNK↓, 1,   p‑JNK↑, 2,   MAPK↓, 1,   Mcl-1↓, 1,   p‑p38↓, 2,   p‑p38↑, 1,   survivin↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 1,   tumCV↓, 3,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   BNIP3?, 1,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   P53↑, 1,   cl‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 1,   CDK4↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   E2Fs↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 1,   p‑ERK↓, 3,   HDAC↓, 1,   HDAC1↓, 1,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC8↓, 1,   PI3K↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   TumCG↓, 2,   Wnt↓, 1,  

Migration ⓘ

E-cadherin↑, 2,   MMP2↓, 3,   MMP9↓, 1,   MMPs↓, 1,   N-cadherin↓, 1,   Slug↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TIMP2↑, 1,   TumCI↓, 2,   TumCMig↓, 4,   TumCP↓, 4,   TumMeta↓, 2,   uPA↓, 1,   Vim↓, 1,   Zeb1↓, 2,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   p‑EGFR↓, 1,   HIF-1↓, 1,   Hif1a↓, 3,   NO↓, 1,   VEGF↓, 5,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   CXCR4↓, 1,   IL1β↓, 1,   IL6↓, 3,   Inflam↓, 5,   JAK2↓, 1,   NF-kB↓, 1,   PD-L1↓, 1,   PGE2↓, 2,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   Dose↝, 2,   eff↓, 1,   eff↑, 6,   MDR1↓, 1,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

p‑EGFR↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 3,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   chemoP↑, 3,   chemoPv↑, 1,   cognitive↑, 1,   memory↑, 1,   neuroP↑, 2,   radioP↑, 3,   TumVol↓, 1,  
Total Targets: 125

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 2,   antiOx↑, 8,   Catalase↑, 5,   Ferroptosis↓, 1,   GCLC↑, 1,   GCLM↑, 1,   GPx↑, 3,   GPx4↑, 1,   GSH↓, 1,   GSH↑, 13,   GSR↓, 1,   GSR↑, 1,   GSTs↓, 1,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 6,   lipid-P?, 1,   lipid-P↓, 8,   MDA↓, 8,   MPO↓, 1,   NQO1↑, 1,   NRF2↑, 10,   ROS↓, 19,   ROS↑, 1,   SOD↑, 10,   TAC↑, 2,   Trx↑, 2,   VitC↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 5,   AMPK↑, 1,   AMPK↝, 1,   BUN↓, 1,   LDH↓, 1,   NAD↑, 1,   NADPH↓, 1,   PPARγ↑, 1,   SIRT1↑, 1,   SIRT2↑, 1,  

Cell Death ⓘ

AhR↑, 1,   Akt↑, 1,   Akt↝, 1,   Apoptosis↓, 1,   BAX↑, 1,   Bcl-2↑, 1,   Casp↓, 1,   Casp3↓, 1,   Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↓, 1,   Fas↓, 1,   Ferroptosis↓, 1,   iNOS↓, 9,   JNK↓, 1,   p‑JNK↓, 1,   MAPK↓, 3,   MAPK↝, 1,   necrosis↓, 2,   p38↓, 1,   p‑p38↓, 1,   Telomerase↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   other↑, 1,   other↝, 1,  

Protein Folding & ER Stress ⓘ

GRP78/BiP↓, 1,   HSP27↑, 1,   HSPs↓, 1,   HSPs↑, 1,   XBP-1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 2,   IGF-1↑, 1,   mTOR↑, 1,   mTOR↝, 1,   OCT4↓, 1,   PI3K↝, 1,   PTEN↑, 1,  

Migration ⓘ

5LO↓, 1,   APP↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   Hif1a↓, 3,   NO↓, 4,  

Barriers & Transport ⓘ

BBB?, 1,   BBB↑, 1,   GLUT4↑, 1,   OATPs↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 5,   IFN-γ↓, 4,   IL1↓, 1,   IL10↓, 1,   IL10↑, 2,   IL1α↓, 1,   IL1β↓, 4,   IL2↓, 3,   IL4↓, 4,   IL6↓, 2,   IL6↑, 1,   IL8↓, 2,   Inflam↓, 20,   NF-kB↓, 12,   PGE2↓, 1,   TLR4↓, 2,   TNF-α↓, 11,   TNF-β↓, 1,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   AChE↓, 4,   BChE↓, 1,   BDNF↑, 3,   MAOA↓, 1,   tau↓, 2,   TrkB↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 4,   MAOB↓, 1,   NLRP3↓, 3,   β-Amyloid↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 3,   BioAv↝, 2,   Dose↝, 2,   Half-Life?, 1,   Half-Life↓, 1,   Half-Life↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 5,   AST↓, 3,   creat↓, 1,   EGFR↓, 1,   GutMicro↑, 1,   GutMicro↝, 1,   IL6↓, 2,   IL6↑, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 2,   cognitive↑, 4,   hepatoP↑, 17,   memory↑, 7,   Mood↑, 1,   neuroP↑, 14,   neuroP↝, 1,   OS↑, 2,   RenoP↑, 2,   Strength↑, 1,   toxicity∅, 1,   Weight↓, 1,  
Total Targets: 145

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page